Findings

What do systematic reviews say?

7 questions · 7 findings · 4 reviews · Gynaecological, Neuro-oncology and Orphan Cancer · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 14.3%GRADE not reported 0 · 0%Very low 2 · 28.6%Low 1 · 14.3%Moderate 2 · 28.6%High 1 · 14.3%

Intervention not reported

Other outcomes included uncertainty, pain, sexually related symptoms, dyspnoea, and general symptoms. Data for any of these outcomes were not pooled due to considerable heterogeneity across all aspects. Magnitudes of effect were not reported · individuals with any cancer at any stage

1 finding from 1 review

Telephone interventions for symptom management in adults with cancer 2020 · Cochrane Headline outcomes only
no estimate extracted
2 participants
Very low

Whole brain radiation therapy (WBRT) + stereotactic radiosurgery (SRS) vs WBRT

Intracranial progression‐free durationNo. of participants: 400(3 RCTs) · patients with newly diagnosed multiple brain metastases

1 finding from 1 review

Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
High

Intervention not reported

Any intracranial disease progression at 1 year · Patients with brain metastases

The intervention may leads to lower any intracranial disease progression at 1 year (low certainty).

1 finding from 1 review

Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
RR 0.46 [0.35, 0.6]
4 studies · 304 participants
Low

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Progression‐free survival · women with advanced EOC after primary IDS

The review found no eligible studies for this question.

1 finding from 1 review

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Overall survival: Median length of · women with advanced ovarian cancer after PDS

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher overall survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

1 finding from 1 review

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
HR 2.5 [2.13, 2.94]
14 studies · 7988 participants
Moderate

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Progression‐free survival · women with advanced ovarian cancer after PDS

Large‐volume residual disease (LVRD) > 1 cm probably leads to higher progression‐free survival: Median length of compared with no macroscopic residual disease (NMRD) (moderate certainty).

1 finding from 1 review

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
HR 2.1 [1.84, 2.4]
6 studies · 2629 participants
Moderate

Large‐volume residual disease (LVRD) > 1 cm vs NMRD

Overall survival: Median length of · women with advanced EOC after primary IDS

It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with no macroscopic residual disease (NMRD) (very low certainty).

1 finding from 1 review

Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after… 2022 · Cochrane Headline outcomes only
HR 2.23 [1.49, 3.34]
1 study · 343 participants
Very low